Navigation Links
Advanced Life Sciences Announces First Quarter 2008 Financial Results
Date:5/7/2008

> the three months ended March 31, 2007. The decrease in R&D expense is

related to lower clinical development and manufacturing costs associated

with the Company's lead product cethromycin.

* General and administrative expense. General and administrative expense

increased $0.2 million to $1.7 million for the three months ended

March 31, 2008. The increase was attributable to costs associated with

cethromycin national advisory board meeting costs and higher

compensation and benefit expenses.

Year-to-Date 2008 Achievements:

* Attended the FDA Anti-Infectives Advisory Committee meeting that

discussed non-inferiority margins in CAP clinical trials on April 1

and 2, 2008 and held a conference call to provide management's

understanding of the Advisory Committee meeting to investors on April 3,

2008;

* Conducted a meeting with FDA on April 7, 2008 to discuss the anticipated

NDA submission in CAP and provided a summary of the outcome to investors

via conference call on April 10, 2008;

* Released results of our successful thorough QT study of cethromycin;

* Provided regulatory updates to multiple potential partners and advanced

negotiations regarding the commercial development of cethromycin as a

treatment for CAP;

* Met with the national advisory board for cethromycin consisting of

thought leaders in the area of respiratory tract infections and

antibiotic therapies to confirm the regulatory and development strategy;

* Advanced the development of ALS-357: received approval from the

Northwestern University Institutional Review Board (IRB) of the protocol

for the planned Phase I/II melanoma program.

Remaining Objectives for 2008

* Submit NDA for cethromycin in CAP;

* Finalize negotiations with potential commercial partners for

cethromycin;

* Conti
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
5. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
6. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
7. Advanced Life Sciences Receives Nasdaq Notification
8. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
11. Advanced Medical Specialties Joins US Oncology Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Limited (NASDAQ GS: SEED) (" Origin ", or the " ... China , today announced that the Company will ... 2014, before the market opens on Thursday, January 8, 2015. ... 8, 2015, at 8:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial +1-888-346-8982 in ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite ... that they have joined forces to support Canadian entrepreneurs tackling ... Virgin Group Founder was at the MaRS Centre to announce ... national impact venture fund. This fund has $1 million in ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
(Date:12/13/2014)... Washington, USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... rise, despite less rosy indicators in overall global economic ... society for optics and photonics , said in a ... International Conference) on 5 December at the National Chung ... solar energy, which is being integrated into future energy ...
(Date:12/13/2014)... New York, New York (PRWEB) December 13, 2014 ... expansion of its global network and Cold Chain capabilities, ... new Control Tower in Paris, France, to serve Life ... brand new facility equipped with a controlled-ambient warehouse, will ... in-transit storage for vaccines and investigational drugs, patient-clinical specimens, ...
Breaking Biology Technology:Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2
... , , STAMFORD, Conn. ... and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced ... Intermezzo ((R)) (zolpidem tartrate sublingual tablet) in the United States. If ... ((R)) has the potential to be the first prescription sleep aid ...
... ... Terrosa Technologies, a provider of Cloud and SaaS ... world wide sales, marketing and distribution responsibilities with Integrated Clinical ... collaboration Clinical Trial Management System (CTMS) tool for the pharmaceutical ...
... time bomb, a deadly mechanism that can be used against ... Universiteit Brussel (VUB) were able to determine the structure and ... for finding ways to set the clock on this internal ... new class of antibiotics. The research was accepted for ...
Cached Biology Technology:Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 2Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 3Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 4Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 5Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 6Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 7Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3Bacteria pack their own demise 2Bacteria pack their own demise 3
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... native flora is in sourcing genetically diverse seed not ... seed. "A common belief is that local native ... projects," says Dr Linda Broadhurst from CSIRO, Australia,s national ... that local seed is adapted to local conditions and ...
... A wild fungus has been found to produce a ... microscopic fungus, known as Gliocladium roseum (NRRL ... rainforest. Gary Strobel of Montana State University ... and that the particular diesel components produced can be ...
... discovered a metabolic deficiency in pancreatic cancer cells that ... deadliest of all cancers. Published in the October ... study results indicate that pancreatic cancer cells cannot produce ... in cell division, immune function and hormone regulation. By ...
Cached Biology News:Obscure fungus produces diesel fuel components 2UC Davis researchers discover Achilles' heel in pancreatic cancer 2UC Davis researchers discover Achilles' heel in pancreatic cancer 3
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Request Info...
Amyloid stain....
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Biology Products: